The successful playbook for rare disease drug development, including involving patients and advocates in early stages, could help boost efforts to bring new neonatal products to market.
Neonatal drug development has fallen behind despite legislation to incentivize pediatric research. The Best Pharmaceuticals for Children Act (BPCA) and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?